Cipher’s leadership has decades of experience and a proven record of success in all facets needed to efficiently develop and commercialize dermatology products. Dedication to our vision is paramount to our success as we expand our product offerings and presence in North America.
Mr. Tessarolo joined Cipher as President & Chief Executive Officer of Cipher on April 17, 2017. Mr. Tessarolo most recently held the position of Vice President & General Manager with Celgene Corporation, where he was responsible for leading their U.S. Inflammation & Immunology business. He contributed to the substantial expansion of the U.S. business in 2016, which was led by the rapid growth of Otezla for plaque psoriasis and psoriatic arthritis.
Prior to joining Celgene in September 2015, Mr. Tessarolo led the launch of Actavis, plc’s Canadian Specialty Pharmaceutical Division, serving as President & General Manager – Canada of Actavis Specialty Pharmaceuticals Co. Under his leadership, Mr. Tessarolo established a Canadian business of over 140 employees and $190 million in revenues, leading his team through several new product launches and the successful integration of multiple company acquisitions, including Warner Chilcott, Forest Labs, and Allergan.
Prior to joining Actavis in 2011, Mr. Tessarolo held a number of positions of increasing responsibility with Biovail Pharmaceuticals Canada, culminating in his appointment to the position of Vice President and General Manager. Mr. Tessarolo had direct oversight and accountability for country strategy, operations, business development and financial responsibilities for each of the Canadian entities he has led.
Mr. Tessarolo received his B.A. in Economics from Carleton University and has attended the Advanced Management Program for General Management at the Ross School of Business, University of Michigan.
Stephen Lemieux, who has more than 13 years of public company experience, most recently served as Vice President and Chief Financial Officer of Nuvo Pharmaceuticals (TSX:NRI) ("Nuvo"), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. He was appointed Chief Financial Officer of Nuvo in January 2012. In his role, Mr. Lemieux was responsible for all of Nuvo's financial operations as well as information technology, manufacturing, human resources and planning. Mr. Lemieux's transactional experience includes licensing and asset sales, debt and equity financing, acquisitions, corporate reorganizations and plans of arrangement.
Prior to joining Nuvo in 2007, Mr. Lemieux was the Corporate Controller at Martinrea International Inc., a Tier One automotive supplier. Prior to joining Martinrea, Mr. Lemieux was the Assistant Controller at Magna Powertrain (formerly Tesma International Inc.) and had previously held the position of Manager, Global Financial Reporting. Tesma was a Tier One automotive supplier and a public company listed on the TSX and NASDAQ. Prior to joining Tesma, Mr. Lemieux worked for Ernst & Young performing audit, restructuring and accounting work for its clients. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting from the University of Toronto.
Ralph brings more than 30 years of dermatologic sales, marketing and management experience in both the US and Canada. Prior to joining Cipher, he was Executive Director of Taro Pharma, the branded dermatology division of Taro Pharmaceuticals. Previously, he was Vice President, Sales for Triax Pharmaceuticals, and held numerous Sr. Level positions during a 14 year career at Medicis, The Dermatology Company, including Sr. Vice President, Sales; President, Medicis Canada; and General Manager for their pediatric and orphan drug subsidiaries. Ralph also founded and directed the consulting firm Ridgeback Associates, providing companies with insight and direction toward specific and measurable sales, marketing, and business development objectives within the pharmaceutical sector.
Joan Chypyha has more than 25 years of experience in the pharmaceutical industry with an emphasis on marketing, sales and business development. Previously Ms. Chypyha was Chief Development Officer of Rhei Pharmaceuticals Ltd.; Vice President, Corporate Development at Barrier Therapeutics Inc.; General Manager of Barrier Therapeutics Canada Inc.; and Founder of Alto Pharmaceuticals Ltd. She also spent 16 years with Hoffman-La Roche in several progressively senior positions, including Business Unit Director, Dialysis and PPN, and Business Unit Director, Dermatology. In this role, Ms. Chypyha was responsible for the management of a specialty sales force that represented Accutane, among other brands. She received her Bachelor of Science from University of Toronto and completed an Executive MBA from Queen’s University.
Linda Angaritis has more than 30 years of experience in the pharmaceutical industry both abroad and in Canada. She has held senior-level positions in multinational brand companies, as well as generics, covering all dosage forms from solid oral dose through to biologics and vaccines. She has extensive experience in manufacturing, regulatory and quality, with a focus on continuous improvement and remediation. Previous positions include Site Quality Head positions at Apotex and Eli Lilly, and Director of Quality Systems and Continuous Improvement at Sanofi Pasteur. Ms. Angaritis received her Pharmacy degree from Rhodes University in South Africa and is a Canadian-registered pharmacist, having completed her PEBC exams in Canada.
Lynne Bulger brings 27 years of experience in the pharmaceutical industry, conducting clinical research trials in phase I-IV and providing strategic medical marketing support in dermatology, rheumatology, osteoporosis and CNS. She has lead drug development programs for topical and systemic therapies in acne, psoriasis, onychomycosis, atopic dermatitis, ichthyosis, photodamage, blistering diseases, seborrheic dermatitis and actinic keratosis. Ms. Bulger developed the first acne mentorship programs in Canada, spearheaded the Canadian Acne Observational Database initiative, and worked with dermatologists to develop improved study outcome measurements in acne, photodamage and atopic dermatitis. She has a special interest in retinoids because of her role in the development and medical management of acitretin and isotretinoin. Previously, Ms. Bulger was Director, Medical Affairs at GSK; Director, Medical Affairs at Stiefel Laboratories; Director, Medical and Regulatory Affairs at Barrier Therapeutics; and Director, Medical Affairs at Hoffmann-La Roche.
Peter Weiler is a seasoned 15-year veteran of the pharmaceutical industry. He has been with Cipher Pharmaceuticals since 2008 and has led the Business Development team since 2011. As Vice President of Business Development, Mr. Weiler has overall responsibility for building Cipher’s dermatology product portfolio, achieving Cipher’s vision for growth through M&A and maximizing the value of Cipher’s legacy assets through development of commercial partnerships in markets outside North America. Prior to Cipher, he spent a number of years in the private equity market, most recently as Senior Director of Investment Analysis with DRI Capital, a highly successful royalty monetization fund specializing in the acquisition of royalty streams from prescription medications. He started his pharmaceutical career by joining the finance team at Eli Lilly Canada before transitioning into roles in market research, first with the oncology group and later with Lilly’s cornerstone diabetes franchise. Mr. Weiler holds an MSc in Biology from the University of Western Ontario and an MBA from the Ivey School of Business at UWO.
Mark Spina has more than 22 years of experience with large, multinational corporations in various finance roles. He joined Cipher’s leadership team in April 2015 through the acquisition of Innocutis Holdings, LLC where he was CFO. For seven years prior, Mr. Spina served as Director of Plant Controlling, Finance & Accounting at Robert Bosch LLC for one of its multi-billion dollar business. Prior to 2007, Mr. Spina spent 14 years with Abbott Laboratories in a number of corporate finance roles within medical, pediatric, consumer and device businesses supporting sales, marketing, operations and research and development. Also while at Abbott Laboratories, Mr. Spina served as Head of Plant IT and Plant Materials Control Manager where he was responsible for the global distribution of plant products. Mr. Spina received his Bachelor of Science degrees in Accounting and Management (with a concentration in Finance) from Purdue University. Currently, he is a Certified Public Accountant registered with the Illinois CPA Society and a member of the American Institute of Certified Public Accountants. His community service roles include Treasurer of the Board of Directors for Central Virginia Federal Credit Union and Board Member for Lynchburg Junior Achievement.